Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Anthony R. Mato, MD

Anthony R. Mato, MD Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Mato is employed by Penn Medicine.

Request an Appointment

Not accepting new patients

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Patient Comments

Clinical Specialties


  • Hematology
  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 2008
  • Internal Medicine, 2005
  • Medical Oncology, 2008

Clinical Expertise:

  • Chronic Lymphocytic Leukemia (CLL)
  • Lymphoma

Practice Locations and Appointments

  • Abramson Cancer Center

    Perelman Center for Advanced Medicine West Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-7366 (PENN)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: State University of New York at Buffalo
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American College of Physician Executives, National American Society of Clinical Oncology, National American Society of Hematology, National Celgene Corporation: A Phase 3B randomized study of lenalidomide(CC-5013) plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma , National National Cancer Institute , National

Hospital Affiliation

Dr. Mato is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Selected Publications:

Landsburg D, Falkiewicz M, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill B, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy N, Singavi A, Fenske TS, Chavez J, Kaplan J, Behdad A, Petrich A, Bast MA, Vose JM, Olszewski A, Costa C, Lansigan F, Gerson J, Barta SK, Calzada O, Cohen JB, Lue J, Amengual J, Rivera X, Persky D, Peace D, Nathan S: Outcomes of double hit lymphoma patients who achieve first complete remission Journal of Clinical Oncology : 2017.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Karbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ: Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi- Center Study of 683 Patients Annals of Oncology 28 (5): 1050-1056,2017.

Catherine Daniel: BCL-2 As a Therapeutic Target in Chronic Lymphocytic Leukemia Hematology & Oncology 15 (3): 210-218,2017.

Nabhan C, Mato A, Flowers CR, Grinblatt DL, Lamanna N, Weiss MA, Davids MS, Swern AS, Bhushan S, Sullivan K, Flick DE, Kiselev P, Sharman: Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: Prospective evaluation on 455 patients treated in the United States BMC Cancer 17 (1): 198,2017.

Mato AR, Timlin C, Ujjani C, Skarbnik A, Howlett C, Banerjee R, Nabhan C: Comparable outcomes in Chronic Lymphocytic Leukemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-center study British Journal of Hematology : 2017.

Schachter LG: An update on immunotherapies including chimeric antigen receptor T-cells therapy and stem cell transplantation in chronic lymphocytic leukemia Translational Cancer Research : 2017.

Nabhan C: Economic Modeling of the Cost of Chronic Lymphocytic Leukemia Therapy: It Is About the Model Journal of Clinical Oncology : 2017.

Anthony R Mato, Meghan C Thompson, Chadi Nabhan, Jakub Svoboda: Chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia: a narrative review Clinical Lymphoma Myeloma and Leukemia : 2017.

Allison M Winter, Daniel J Landsburg, Anthony R Mato, Krista Isaac, Francisco J Hernandez-Ilizaliturri, Nishitha Reddy, Stephen Smith, Mazyar Shadman, Mitchell R Smith, Paolo Caimi, Deepa Jagadeesh: A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib. BLOOD : 2017.

Chadi Nabhan: Emerging Strategies in Treating Double Hit Lymphomas Clinical Lymphoma Myeloma and Leukemia : 2017.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-160
3400 Civic Center Blvd

Philadelphia, Pa 19104
Phone: (215) 615-7361
Patient appointments: 800-789-7366 (PENN)

Related Links